EMulate Therapeutics, Inc., a clinical-stage therapeutic device company developing non-invasive treatments for cancers and other serious diseases, announced it has entered into an exclusive agreement for the distribution of the company’s proprietary Voyager ulRFE® system for treatment of patients with selected brain cancer indications – both recurrent and newly diagnosed glioblastoma (GBM) and diffuse midline glioma (DMG), in India. The exclusive distributor is Sayre Therapeutics (Sayre), a Bangalore, India-based company that provides access to differentiated medical solutions to patients and clinicians in emerging markets by identifying high unmet needs across the healthcare continuum. Sayre Therapeutics is a specialty biotech dealing with innovative treatments, medical devices and diagnostics commercialization in South Asia. Sayre is backed by institutional investors and has a portfolio of oncology, interventional oncology and immunology drugs, drug delivery devices and diagnostics.
Chris Rivera, EMulate Therapeutics President and Chief Executive Officer, made the announcement stating, “This agreement with Sayre is EMulate’s second agreement with a highly-regarded international firm, the first being with Teijin Pharma Limited in Japan. Sayre is a natural fit for distributing the Voyager system as they focus on orphan therapeutics, especially cancer, as well as their current detailing of brain cancer doctors to promote products to treat GBM and DMG.”
“We are very excited about this agreement for Voyager and Hӕlo™ distribution with Sayre,” stated Michael Mischke-Reeds, Senior Vice President of Business Development for EMulate Therapeutics. “The agreement continues EMulate’s business plan for wide-spread international distribution of the Voyager and Hӕlo system with the potential to treat a number of forms of cancers and other serious diseases in children and adults.”
Ravindranath Kunjithai, Vice President and Head, Medical & Regulatory affairs at Sayre Therapeutics mentioned that “GBM is an aggressive and common malignant tumor, affecting 5000 to 7000 patients in India, with poor prognosis and limited treatment options. Since 2003 until now there have been only two FDA approvals, pointing to the unmet therapeutic need in this field. The Voyager ulRFE system is a novel concept that has shown good results in the clinical trials for GBM. Emulate has developed this ulRFE technology into a non-invasive and easy to use device in home/office surroundings, that will have far reaching positive outcomes on the Indian GBM patients.”
“Voyager is in alignment with our philosophy of launching first-in-class products that improve survival and quality of life of Indian patients,” stated Shukrit Chimote, Chief Executive Officer at Sayre Therapeutics. “Sayre Therapeutics is excited to strengthen its neuro-oncology portfolio with the addition of Voyager and Hӕlo to the existing targeted drug-delivery options, such as carmustine wafers This further reinforces our commitment to the burgeoning home healthcare market for life threatening diseases. EMulate received ISO 13485:2016, a prerequisite for a CE Mark, in May of this year; as well as receiving MDSAP (Medical Device Single Audit Program) certification in July, which is pertinent to registration in other geographies. An application for a CE Mark in the European Union was announced in August. – Benzinga